目的 探討班布特羅聯(lián)合莫西沙星治療慢性阻塞性肺疾病急性加重期的臨床療效。方法 選取2012年1月-2016年1月在烏魯木齊市友誼醫(yī)院治療的慢性阻塞性肺疾病急性加重期患者88例，隨機分為對照組和治療組，每組各44例。對照組睡前口服鹽酸莫西沙星片，0.4 mg/次，1次/d；治療組在對照組的基礎上睡前口服鹽酸班布特羅片，10 mg/次，1次/d。兩組患者均連續(xù)治療8 d。觀察兩組臨床療效，比較兩組患者的白細胞計數(shù)（WBC）、中性粒細胞（NBC）和C反應蛋白（CRP）以及血氣指標變化情況。結果 治療后，對照組和治療組患者的總有效率分別為77.3%、90.9%，兩組總有效率比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組患者的WBC、NBC和CRP均較治療前顯著下降，同組治療前后差異具有統(tǒng)計學意義（P<0.05）；且治療組上述指標的改善程度優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者血氧分壓（pO₂）較治療前顯著升高，而二氧化碳分壓（pCO₂）較治療前顯著降低，同組比較差異具有統(tǒng)計學意義（P<0.05）；且治療組這些觀察指標的改善程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結論 班布特羅聯(lián)合莫西沙星治療慢性阻塞性肺疾病急性加重期具有良好的臨床療效，可以降低患者的氣道阻力，有效控制肺部感染，緩解患者的呼吸困難，改善患者的肺功能，具有一定的臨床推廣應用價值。

Objective To evaluate the clinical efficacies of bambuterol combined with moxifloxacin in treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods Patients (88 cases) with acute exacerbation of chronic obstructive pulmonary disease in Urumqi Friendship Hospital from January 2012 to January 2016 were randomly divided into control and treatment groups, and each group had 44 cases. The patients in the control group were po administered with Moxifloxacin Hydrochloride Tablets before sleeping, 0.4 mg/time, once daily. The patients in the treatment group were po administered with Bambuterol Hydrochloride Tablets before sleeping on the basis of the control group, 10 mg/time, once daily. The patients in two groups were treated for 8 d. After treatment, the efficacy was evaluated, and WBC, NBC, and CRP, and blood gas indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 77.3% and 90.9%, respectively, and there was difference between two groups (P<0.05). After treatment, WBC, CRP, and NBC in two groups were significantly decreased, and the differences were statistically significant in the same group (P<0.05). And the improvement of the observational indexes in the treatment group was significantly better than those in the control group, with significant differences between two groups (P<0.05). After treatment, pO₂ in two groups was significantly increased, but the pCO₂ was decreased, and the differences were statistically significant in the same group (P<0.05). And these observational indexes in the treatment group were significantly better than those in the control group, with significant differences between two groups (P<0.05). Conclusion s Bambuterol combined with moxifloxacin has a good clinical efficacy in treatment of acute exacerbation of chronic obstructive pulmonary disease, can reduce airway resistance with effective controlling of pulmonary infection, dyspnea relieving, and improvement of pulmonary function, which has a certain clinical application value.